cgoncology_cover.jpg
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
16. Dezember 2024 16:05 ET | CG Oncology Inc.
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
cgoncology_cover.jpg
CG Oncology Announces Pricing of Public Offering
12. Dezember 2024 20:19 ET | CG Oncology Inc.
CG Oncology Announces Pricing of Public Offering
cgoncology_cover.jpg
CG Oncology Announces Proposed Public Offering
11. Dezember 2024 06:17 ET | CG Oncology Inc.
CG Oncology Announces Proposed Public Offering
cgoncology_cover.jpg
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
06. Dezember 2024 08:00 ET | CG Oncology Inc.
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
cgoncology_cover.jpg
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
05. Dezember 2024 07:00 ET | CG Oncology Inc.
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle
cgoncology_cover.jpg
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
02. Dezember 2024 08:00 ET | CG Oncology Inc.
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
cgoncology_cover.jpg
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
20. November 2024 08:00 ET | CG Oncology Inc.
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
cgoncology_cover.jpg
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
11. November 2024 08:00 ET | CG Oncology Inc.
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Musc
cgoncology_cover.jpg
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
08. August 2024 08:23 ET | CG Oncology Inc.
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
cgoncology_cover.jpg
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
06. Juni 2024 12:14 ET | CG Oncology Inc.
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab